Asieris Pharmaceuticals
Manufacturing · Pennsylvania, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
201 King of Prussia Rd Ste 650, Radnor, ...Website
www.asieris.comRevenue
$14.4 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Asieris Pharmaceuticals
Asieris Pharmaceuticals is dedicated to improving human health and preserving patients' dignity through innovative therapies focused on genitourinary tumors and women's health. The company offers products such as Vesique® (APL-1202) and Cevira® (APL-1702), with a strong emphasis on urologic oncology and a robust gynecology pipeline. Asieris engages in global partnerships and collaborations to enhance its research and development capabilities. Their mission is to provide integrated diagnosis and treatment solutions while addressing both early- and late-stage medical needs.Explore more
Asieris Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Asieris Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Asieris Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Asieris Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Asieris Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Asieris Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Asieris Pharmaceuticals launches new products
Click to see if Asieris Pharmaceuticals had a recent Job posting/layoffs
Check if Asieris Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Asieris Pharmaceuticals
Recommended Actions
Reach out to Masked Content who joined Asieris Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Asieris Pharmaceuticals
Compare insights from companies similar to Asieris Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Asieris Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Asieris Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Asieris Pharmaceuticals.
Asieris Pharmaceuticals Tech Stack
A closer look at the technologies used by Asieris Pharmaceuticals
Most Recent Scoops
Person-Based
Person-Based
Person-Based
New Hire
Executive Move
Asieris Pharmaceuticals News & Media
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
OSLO, Norway, March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from...Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
OSLO, Norway, March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from...Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe
OSLO, Norway, Feb. 27, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its marketing authorization application (MAA) for Cevira® (APL-1702) for the treatment of high-grade...Asieris Pharmaceuticals Releases 2025 Semi-Annual Report with Sustained Commercial Momentum and Breakthrough Innovation Poised for Launch
SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2025 Semi-Annual Report, highlighting strong growth momentum. The company's Commercial Operation 2.0 has begun to deliver results, with sales rising steadily and first-half targets achieved. APL-1702, a...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Asieris Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Asieris Pharmaceuticals is dedicated to improving human health and preserving patients' dignity through innovative therapies focused on genitourinary tumors and women's health. The company offers products such as Vesique® (APL-1202) and Cevira® (APL-1702), with a strong emphasis on urologic oncology and a robust gynecology pipeline. Asieris engages... Read More
